Therapeutic antibody therapy is well established. Monoclonals are produced outside the body and administered by infusion (passive immunisation). A next step is to teach the body to produce the antibodies itself by active immunisation. A major stumbling block for both passive and active immunisation is often the inability to generate potential antibodies, especially when the target antigen is complex in nature (GPCRs or ion-channels) or blocked by patents.

Pepscan's proven technologies provide an elegant and effective way to arrive at superior immunogens for monocolonals and therapeutic vaccines.

Pepscan focusses on cancer immunotherputics. Its strong pipeline consists of both therapeutic vaccines and monocolonals. The most advanced product is in Phase II clinical testing.

Speaker Profile

Joost van Bree, PhD, Chief Executive Officer

Holds an MSc in Pharmacy and a PhD in Pharmacology, both from Leiden University (The Netherlands). He has worked in various international management positions in the fields of pharmaceutics, clinical pharmacology, drug development and regulatory affairs with Sandoz (now Novartis) in Switzerland, Pharmachemie/OPG and most recently before joining Pepscan at Pharming, where he held the position of VP Clinical Development and Regulatory Affairs. Joost carries over 15-years industry experience in successfully bringing conventional and biotech drug through development and regulatory approval. He has extensive hands-on experience in structuring, negotiating and managing commercial pharmaceutical partnerships and co-development programs. In addition, he brings the experience of raising funds of over EUR 100 Million with venture capital